Figure 4

miR-375 modulates trastuzumab resistance of HER2-positive breast cancer xenografts. Nude mice were inoculated in the mammary fat pad with trastuzumab-resistant SKBr-3 cells overexpressing pre-miR-375 or control pre-miRNA to allow tumor development. Mice were intravenously injected with 10 mg/kg trastuzumab twice a week. A. Tumor volume in the trastuzumab-treated mice. Data are represented as the mean ± SD of six mice. *P <0.05. B. Tumor weight at the end of the treatment period (45 days after first trastuzumab injection). The bars represent the mean ± SD of six mice. C. Kaplan-Meier survival curves of the trastuzumab-treated mice (n = 6).